Optimizing outcomes with bevacizumab by better targeting patients and tumors.

DeMichele, Angela; Fox, Kevin R

DeMichele, Angela; Fox, Kevin R.

Affiliation

DeMichele A; Breast Cancer Program, Abramson Cancer Center, University of Pennsylvania, USA.

Oncology (Williston Park) ; 23(4): 339-40, 2009 Apr 15.

Article in En | MEDLINE | ID: mdl-19476263

Subject(s)

Angiogenesis Inhibitors/administration & dosage; Antibodies, Monoclonal/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Angiogenesis Inhibitors/adverse effects; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Bevacizumab; Breast Neoplasms/metabolism; Breast Neoplasms/mortality; Breast Neoplasms/secondary; Disease-Free Survival; Evidence-Based Medicine; Female; Humans; Patient Selection; Time Factors; Treatment Outcome

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Angiogenesis Inhibitors / Vascular Endothelial Growth Factor A / Antibodies, Monoclonal Limits: Female / Humans Language: En Year: 2009 Type: Article

Search on Google

XML

PubMed Links